[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2012014070A - Composiciones metformina-orlistat. - Google Patents

Composiciones metformina-orlistat.

Info

Publication number
MX2012014070A
MX2012014070A MX2012014070A MX2012014070A MX2012014070A MX 2012014070 A MX2012014070 A MX 2012014070A MX 2012014070 A MX2012014070 A MX 2012014070A MX 2012014070 A MX2012014070 A MX 2012014070A MX 2012014070 A MX2012014070 A MX 2012014070A
Authority
MX
Mexico
Prior art keywords
orlistat
metformin
compositions
monotherapy
hypoglycemic
Prior art date
Application number
MX2012014070A
Other languages
English (en)
Inventor
Patricia María Rodríguez Bernal
María Del Lourdes García Mondragón
Marisol Juana Gómora Pacheco
Original Assignee
Landsteiner Scient S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landsteiner Scient S A De C V filed Critical Landsteiner Scient S A De C V
Priority to MX2012014070A priority Critical patent/MX2012014070A/es
Priority to JP2015545409A priority patent/JP2016501227A/ja
Priority to EP13860230.5A priority patent/EP2926813A4/en
Priority to PCT/MX2013/000133 priority patent/WO2014088386A1/es
Priority to US14/648,992 priority patent/US20150342921A1/en
Publication of MX2012014070A publication Critical patent/MX2012014070A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una combinación de un hipoglucemiante, metformina, y un inhibidor irreversible de las lipasas gástrica y pancreática en el intestino, orlistat, para un mejor control de la obesidad que con el empleo de monoterapia con cada uno de ellos; dicha composición proporciona dosis "bajas" de ambos fármacos para minimizar efectos secundarios y aprovechar el efecto sinérgico de ambos compuestos.
MX2012014070A 2012-12-03 2012-12-03 Composiciones metformina-orlistat. MX2012014070A (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MX2012014070A MX2012014070A (es) 2012-12-03 2012-12-03 Composiciones metformina-orlistat.
JP2015545409A JP2016501227A (ja) 2012-12-03 2013-11-01 メトホルミン−オルリスタット組成物
EP13860230.5A EP2926813A4 (en) 2012-12-03 2013-11-01 METFORMIN-Orlistat COMPOSITIONS
PCT/MX2013/000133 WO2014088386A1 (es) 2012-12-03 2013-11-01 Composiciones metformina-orlistat
US14/648,992 US20150342921A1 (en) 2012-12-03 2013-11-01 Metformin-orlistat compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012014070A MX2012014070A (es) 2012-12-03 2012-12-03 Composiciones metformina-orlistat.

Publications (1)

Publication Number Publication Date
MX2012014070A true MX2012014070A (es) 2014-06-23

Family

ID=50883733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014070A MX2012014070A (es) 2012-12-03 2012-12-03 Composiciones metformina-orlistat.

Country Status (5)

Country Link
US (1) US20150342921A1 (es)
EP (1) EP2926813A4 (es)
JP (1) JP2016501227A (es)
MX (1) MX2012014070A (es)
WO (1) WO2014088386A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
WO2010045529A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010045522A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity

Also Published As

Publication number Publication date
EP2926813A1 (en) 2015-10-07
EP2926813A4 (en) 2016-05-25
JP2016501227A (ja) 2016-01-18
WO2014088386A1 (es) 2014-06-12
US20150342921A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
MX2012015188A (es) Composiciones de liberacion controlada con efecto de alimentos reducido.
MX346665B (es) Composiciones pesticidas y procedimientos relacionados con estas.
IN2014CN04676A (es)
PH12015501720A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
JO3452B1 (ar) بنزاميدات أمينو اريل مغاير كمثبطات كيناز
PH12015501392A1 (en) Pesticidal compositions and processes related thereto
MX2015010377A (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos.
MX355431B (es) Composiciones plaguicidas y procesos relacionados con dichas composiciones.
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
TN2014000449A1 (en) Complement pathway modulators and uses thereof
MX2013009252A (es) Composiciones y procesos relacionados con los mismos plaguicidas.
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
IN2014DN10670A (es)
NZ718373A (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
PH12014501032A1 (en) 2-thiopyrimidinones
MX362879B (es) Usos novedosos.
MY165075A (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX355415B (es) Composiciones y metodos para tratar enfermedades y trastornos que son modulados por una vía de transducción de señales.
PH12014501313B1 (en) Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
MX2012014070A (es) Composiciones metformina-orlistat.
MX350569B (es) Composicion farmaceutica estable para el tratamiento de osteoporosis.
MY161769A (en) Pharmaceutical composition for treating hcv infections